Literature DB >> 10997965

Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia.

R Möhle1, M Schittenhelm, C Failenschmid, F Bautz, K Kratz-Albers, H Serve, W Brugger, L Kanz.   

Abstract

The chemokine stromal cell-derived factor-1 (SDF-1) that is released by bone marrow (BM) stromal cells and contributes to stem cell homing may also play a role in the trafficking of leukaemic cells. We analysed SDF-1-induced intracellular calcium fluxes in leukaemic blasts from the peripheral blood of patients with newly diagnosed acute myeloid leukaemia (AML) and lymphoblastic leukaemia (B-lineage ALL), determined the effect of BM stromal cell-conditioned medium on in vitro transendothelial migration (TM) and measured expression of the SDF-1 receptor, CXCR4, by flow cytometry. AML FAB M1/2 blasts did not show calcium fluxes and TM was not stimulated. In myelomonocytic AML (M4/5), however, SDF-1 induced significant calcium fluxes and TM was increased twofold by the conditioned medium. M3 and M4 blasts with eosinophilia (M4eo) showed intermediate activity and M6 blasts showed no functional activity. In ALL, strong calcium fluxes and increased TM (2.5-fold) were observed. Accordingly, expression of CXCR4 was low in undifferentiated (M0) AML, myeloid (M1/2) AML and erythroid (M6) AML, but high [mean fluorescence (MF) > 50] in promyelocytic (M3) AML, myelomonocytic (M4/5) AML and B-lineage ALL. We conclude that, in AML, SDF-1 is preferentially active in myelomonocytic blasts as a result of differentiation-related expression of CXCR4. Functional activity of SDF-1 and high expression of CXCR4 in B-lineage ALL is in accordance with the previously described activity of SDF-1 in early B cells. SDF-1 may contribute to leukaemic marrow infiltration, as suggested by increased CXCR4 expression and migratory response in BM-derived blasts compared with circulating cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997965     DOI: 10.1046/j.1365-2141.2000.02157.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  39 in total

1.  A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).

Authors:  Todd M Cooper; Edward Allan Racela Sison; Sharyn D Baker; Lie Li; Amina Ahmed; Tanya Trippett; Lia Gore; Margaret E Macy; Aru Narendran; Keith August; Michael J Absalon; Jessica Boklan; Jessica Pollard; Daniel Magoon; Patrick A Brown
Journal:  Pediatr Blood Cancer       Date:  2017-04-14       Impact factor: 3.167

Review 2.  Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.

Authors:  Marina Konopleva; Yoko Tabe; Zhihong Zeng; Michael Andreeff
Journal:  Drug Resist Updat       Date:  2009-07-25       Impact factor: 18.500

Review 3.  Advances in understanding the leukaemia microenvironment.

Authors:  Yoko Tabe; Marina Konopleva
Journal:  Br J Haematol       Date:  2014-01-09       Impact factor: 6.998

4.  Open conformation of tetraspanins shapes interaction partner networks on cell membranes.

Authors:  Yihu Yang; Xiaoran Roger Liu; Zev J Greenberg; Fengbo Zhou; Peng He; Lingling Fan; Shixuan Liu; Guomin Shen; Takeshi Egawa; Michael L Gross; Laura G Schuettpelz; Weikai Li
Journal:  EMBO J       Date:  2020-08-16       Impact factor: 11.598

Review 5.  Understanding the bone marrow microenvironment in hematologic malignancies: A focus on chemokine, integrin, and extracellular vesicle signaling.

Authors:  Edward Allan Racela Sison; Peter Kurre; Yong-Mi Kim
Journal:  Pediatr Hematol Oncol       Date:  2017-12-06       Impact factor: 1.969

6.  Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

Authors:  Zhihong Zeng; Yue Xi Shi; Ismael J Samudio; Rui-Yu Wang; Xiaoyang Ling; Olga Frolova; Mark Levis; Joshua B Rubin; Robert R Negrin; Elihu H Estey; Sergej Konoplev; Michael Andreeff; Marina Konopleva
Journal:  Blood       Date:  2008-10-27       Impact factor: 22.113

7.  Interaction of SDF-1alpha and CXCR4 plays an important role in pulmonary cellular infiltration in differentiation syndrome.

Authors:  Jin Zhou; Longhu Hu; Zhe Cui; Xian Jiang; Guifang Wang; Geoffrey W Krissansen; Xueying Sun
Journal:  Int J Hematol       Date:  2010-03       Impact factor: 2.490

Review 8.  Role of CXCL1 in tumorigenesis of melanoma.

Authors:  Punita Dhawan; Ann Richmond
Journal:  J Leukoc Biol       Date:  2002-07       Impact factor: 4.962

9.  CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.

Authors:  Ye Chen; Rodrigo Jacamo; Marina Konopleva; Ramiro Garzon; Carlo Croce; Michael Andreeff
Journal:  J Clin Invest       Date:  2013-05-08       Impact factor: 14.808

10.  PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia.

Authors:  Sofie Struyf; Evemie Schutyser; Mieke Gouwy; Klara Gijsbers; Paul Proost; Yves Benoit; Ghislain Opdenakker; Jo Van Damme; Geneviève Laureys
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.